HAS3 and lip and oral cavity carcinoma: Together, the pharmacological inhibition of HAS enzymatic activity or HAS3 neutralization mimicked HAS3 depletion effects on oral cancer cells, supporting that HA accumulation was accountable for oncogenic actions mediated by HAS3.